In the following video, Motley Fool health-care analyst David Williamson discusses Zoegenix's 30% leap, as the FDA delays approval for its pain medication Zohydro. A delay would make very little sense if the FDA were planning to reject the drug, and the company has stated that the FDA says this delay will be brief. David tells us why this is surprising, and what is driving the market's reaction.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report " 3 Stocks That Will Help You Retire Rich " names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Is Zoegenix on the Verge of FDA Approval? originally appeared on Fool.com.David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.